An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions

Inclusion Criteria

• •Minimum of 12 months continuous enrolment in the EHR databases with medical and pharmacy coverage measured as continuously receiving medical care from health providers contributing to the EHR system.
• •No recorded prescription of finerenone prior to the index date.
• •Age 18 years or older as of the index date.
• •T2D diagnosis at any point before (and including) the index date using the same algorithms applicable to the specific data source as in previous studies of the FIRST program.
• •CKD stages 2-4 related to eligibility will be defined according to the presence of the following criteria at any point before (and including) the index date:
• •* A diagnosis code indicating CKD stage 2, 3, 4, or stage unspecified OR
• •* Two Urinary Albumin-to-Creatinine Ratio (ACR) test results ≥ 30 mg/g separated by at least 90 days and no more than 540 days OR
• •* Two different eGFR test results ≥ 15 mL/min/1.73 m\*2 AND \< 60 mL/min/1.73 m\*2 separated by at least 90 days and no more than 540 days.